Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=40 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
N/A N=36 Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
Endometrial Carcinoma
Primary: Expression of Cell Cycle-related Proteins — 46.1; 0.8; 0.7 score on a scale — p=0.033
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 2 N=38 Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Endometrial Cancer
Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months
Phase 2 N=70 BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Advanced Endometrial Cancer
Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=35 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
N/A N=50 Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Endometrial Cancer · Chemotherapy Effect · Quality of Life
Primary: The Impact in Terms of Overall Quality of Life of Adjuvant Chemotherapy by the QLQ-C30 Questionnaire — 61.7; 71.1 units on a scale
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=50 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
Phase 2 N=40 A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Ovarian Clear Cell Carcinoma
Primary: Six Month Progression Free Survival Rate — 8 Participants
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Phase 2 N=11 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 2 N=133 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Endometrial Cancer
Primary: Objective Response Rate (ORR) — 14.3 Percentage of participants
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 2 N=50 Gemcitabine in Ovarian Cancer
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Phase 2 N=33 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Phase 2 N=30 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
Endometrial Cancer · Uterine Carcinosarcoma
Primary: Treatment Related Overall Response Rate — 30 participants
Phase 3 N=1,381 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Recurrent Uterine Corpus Carcinoma · Stage IIIA Uterine Corpus Cancer AJCC v7 · Stage IIIB Uterine Corpus Cancer AJCC v7
Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants